Sarda Proteins Limited has announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company's Board of Directors convened on February 14, 2026, to review and approve these quarterly financial statements in compliance with regulatory requirements.

Board Meeting Details

The Board meeting was conducted on Saturday, February 14, 2026, commencing at 2.30 pm and concluding at 3.15 pm. During this session, the directors considered and approved the unaudited financial results for both the quarter and nine-month period ending December 31, 2025.

Regulatory Compliance and Submission

The financial results were submitted to the Corporate Relationship Department of the Bombay Stock Exchange Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company operates under scrip code 519242 with ISIN INE995U01011.

Khilan Savaliya, Director with DIN 08790209, signed the submission documents on behalf of Sarda Proteins Limited. The results were accompanied by a Limited Review Report issued by the company's statutory auditors.

Independent Auditor's Review

M/s. A H Mandaliya & Associates, Chartered Accountants (FRN: 146705W), conducted the independent review of the unaudited standalone financial results. Partner Hiren J. Mandaliya (Mem. No. 140193) signed the review report on February 14, 2026, from Ahmedabad.

Audit Opinion and Standards

The auditors conducted their review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. The financial results were prepared following Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) and other accounting principles generally accepted in India.

Based on their review, the auditors found no material misstatements in the accompanying financial results. The review confirmed that the statements disclosed all required information in accordance with SEBI listing regulations and were prepared using appropriate recognition and measurement principles.

Sarda Proteins has announced significant changes to its board of directors, appointing three new Additional Directors for five-year terms. This move comes as the company maintains a stable financial position, as reflected in its latest balance sheet data.

Board Expansion

The company's Board of Directors has approved the appointment of three Additional Directors, each for a term of five years, subject to shareholder approval:

1. Mr. Bipinkumar Babubhai Savalia (DIN: 03339121)
2. Mr. Gunvantray Jayantilal Zaladi (DIN: 11253353)
3. Mr. Shivam Gunvantray Zaladi (DIN: 11251860)

These appointments are expected to strengthen Sarda Proteins' leadership structure. The new directors bring experience in commerce, security markets, and business administration, which could potentially drive the company's strategic direction and growth in the coming years.

Financial Position

Alongside these leadership changes, Sarda Proteins' latest balance sheet data shows a stable financial position:

The company has seen a modest increase in its total assets, growing by 8.33% year-over-year to ₹2.60 crore. Current assets have also shown growth, increasing by 8.70% to ₹2.50 crore. While shareholders' capital and total equity remain unchanged at ₹2.40 crore, the company has reported current liabilities of ₹0.20 crore, up from zero in the previous year.

These figures suggest that Sarda Proteins is maintaining a stable financial foundation while potentially positioning itself for future growth through its board expansion.

The appointment of new directors with diverse expertise, coupled with the company's steady financial metrics, may indicate Sarda Proteins' intent to explore new opportunities or strengthen its market position. Shareholders and market watchers will likely keep a close eye on how these leadership changes might influence the company's strategic direction and financial performance in the medium to long term.

As always, investors are advised to conduct their own research and consider their financial goals before making investment decisions based on these developments.